Fender Team

Team leader : Pascal Fender


Adenoviruses are non-enveloped DNA viruses that infect many animal species. In humans, Adenoviruses are responsible for acute respiratory infections, sometimes fatal, and no specific treatment exists to date. Paradoxically, Adenoviruses are also the most widely used vectors in human gene therapy clinical trials and have been approved very rapidly in anti-COVID vaccination (Vaxzevria from AstraZeneca, and Jcovden from J&J/Janssen).

The Fender’s team has the goal of using the results obtained in the laboratory and exploiting them to propose societal solutions in the field of vaccinology and targeted antiviral therapies. You will discover by clicking on the icons below: (i) how our biochemical and structural research on adenoviral receptors leads us to the screening of antiviral molecules or (ii) how a non-infectious particle derived from adenoviruses has been modified to serve as a universal vaccine platform that has been validated in pre-clinical infectious diseases (SARS-CoV-2) and in cancer (melanoma).

Emilie Stermann (IR-CNRS)
Léa Pounot (AI-CNRS)
Rafael de Souza Pontes (Visiting Ph-D student)
Felipe Lemes de Araujo (Visiting Ph-D student)

Former Members:
Christopher Chevillard (IE, Oct 2021 - Mar 2023)
Solène Besson (Ph-D Thesis, Oct 2019 - Dec 2022)
Marie-Claire Dagher (CR-CNRS, Sep 2019 - Dec 2021)
Salomé Gallet (Medical Doctor, Jan 2021-Oct 2021)
Marc-André Hograindleur (IE, Jan 2019 - Aug 2021)
Valentin Dettling (Student, Jan 2019 - Apr 2019)
Charles Vragniau (Ph-D Thesis, Oct 2015 - Sep 2018)
Corinne Ducournau (IE, Dec 2013 - Aug 2016)
Manon Mottet (Student, Jan 2014-Jun 2016)